PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
March 14, 2026Neuro-Oncology Pediatrics0 citationsOpen Access

ATRT-08. Exploiting lipid metabolism in atypical teratoid/rhabdoid tumors

View Full Paper
STStefania TocciTHTessa O HouseMCMarissa Coppola

Key Points

  • This research aims to explore lipid metabolism as a potential therapeutic target in atypical teratoid/rhabdoid tumors (AT/RT).
  • Utilized RNA-sequencing on pediatric brain tumor cell lines to analyze lipid metabolism genes.
  • Employed CRISPR/Cas9 to knockout metabolic genes in patient-derived AT/RT cells.
  • Conducted functional genomics and mass spectrometry for metabolic assays.
  • Developed a custom lentiviral library targeting metabolic genes for high throughput assays.
  • AT/RT cells showed significantly upregulated gene expression related to de novo lipogenesis.
  • Knocking out metabolic genes led to reduced cell viability in AT/RT cells.
  • Identified lipid metabolic reprogramming as a unique vulnerability potentially exploitable for therapy.

Abstract

Abstract Background Atypical teratoid/rhabdoid tumors (AT/RT) are extremely aggressive childhood central nervous system tumors that most often affect children age 3 and younger. While there have been some improvements in clinical outcomes with multimodal therapy, significant morbidity and severe toxicities are associated with such therapy. Metabolic pathways are often hijacked in cancer, thus providing tumor cells with the capacity to survive and invade. Importantly, these pathways can be targeted by pharmacologic inhibition, and their regulation is well understood through the basic helix-loop-helix transcription factor, sterol regulatory element binding protein (SREBP). SREBP acts as a master regulator of lipid metabolism. While lipid metabolic reprogramming has been recognized as a hallmark of cancer, it is unknown whether metabolic reprogramming is a characteristic of AT/RT cells, and whether this can be exploited as a therapeutic target. Methods Using in vitro patient-derived AT/RT models, RNA-sequencing, functional genomics, metabolic assays, mass spectrometry, and pharmacologic inhibitors of metabolism, we sought to test the hypothesis that lipid metabolic reprogramming represents a unique dependency in AT/RT. Results First, we utilized RNA-sequencing expression data from hundreds of pediatric brain tumor cell lines and performed enrichment analysis of lipid metabolism genes. AT/RT cells harbor significantly upregulated expression of genes involved in de novo lipogenesis, suggesting these pathways may represent unique vulnerabilities. Harnessing CRISPR/Cas9, we knocked out the most highly expressed metabolic genes in patient-derived AT/RT cells leading to significant attenuation of cell viability. Next, we tested inhibitors of these metabolic pathways in AT/RT cells. Lastly, we designed a custom pool of CRISPR/Cas9 sgRNAs targeting of approximately 3000 metabolism genes. This custom lentiviral library will enable high throughput assays to identify which metabolic genes represent cancer dependencies in AT/RT.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Tocci et al. (2025) studied this question.

synapsesocial.com/papers/69b4ba0818185d8a39802884https://doi.org/10.1093/neuped/wuaf001.008
Ask AI
Helpful
Bookmark
Share
View Full Paper